Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Duchenne Muscular Dystrophy Therapeutics Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Pain Management Drugs
1.2.3 Corticosteroids
1.2.4 Prednisolone
1.2.5 Prednisone
1.2.6 Deflazacort
1.3 Market by Application
1.3.1 Global Duchenne Muscular Dystrophy Therapeutics Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Home Care
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Duchenne Muscular Dystrophy Therapeutics Market Perspective (2018-2033)
2.2 Duchenne Muscular Dystrophy Therapeutics Growth Trends by Region
2.2.1 Global Duchenne Muscular Dystrophy Therapeutics Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Duchenne Muscular Dystrophy Therapeutics Historic Market Size by Region (2018-2023)
2.2.3 Duchenne Muscular Dystrophy Therapeutics Forecasted Market Size by Region (2024-2033)
2.3 Duchenne Muscular Dystrophy Therapeutics Market Dynamics
2.3.1 Duchenne Muscular Dystrophy Therapeutics Industry Trends
2.3.2 Duchenne Muscular Dystrophy Therapeutics Market Drivers
2.3.3 Duchenne Muscular Dystrophy Therapeutics Market Challenges
2.3.4 Duchenne Muscular Dystrophy Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Duchenne Muscular Dystrophy Therapeutics Players by Revenue
3.1.1 Global Top Duchenne Muscular Dystrophy Therapeutics Players by Revenue (2018-2023)
3.1.2 Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Players (2018-2023)
3.2 Global Duchenne Muscular Dystrophy Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Duchenne Muscular Dystrophy Therapeutics Revenue
3.4 Global Duchenne Muscular Dystrophy Therapeutics Market Concentration Ratio
3.4.1 Global Duchenne Muscular Dystrophy Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Duchenne Muscular Dystrophy Therapeutics Revenue in 2022
3.5 Duchenne Muscular Dystrophy Therapeutics Key Players Head office and Area Served
3.6 Key Players Duchenne Muscular Dystrophy Therapeutics Product Solution and Service
3.7 Date of Enter into Duchenne Muscular Dystrophy Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Duchenne Muscular Dystrophy Therapeutics Breakdown Data by Type
4.1 Global Duchenne Muscular Dystrophy Therapeutics Historic Market Size by Type (2018-2023)
4.2 Global Duchenne Muscular Dystrophy Therapeutics Forecasted Market Size by Type (2024-2033)
5 Duchenne Muscular Dystrophy Therapeutics Breakdown Data by Application
5.1 Global Duchenne Muscular Dystrophy Therapeutics Historic Market Size by Application (2018-2023)
5.2 Global Duchenne Muscular Dystrophy Therapeutics Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Duchenne Muscular Dystrophy Therapeutics Market Size (2018-2033)
6.2 North America Duchenne Muscular Dystrophy Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2018-2023)
6.4 North America Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Duchenne Muscular Dystrophy Therapeutics Market Size (2018-2033)
7.2 Europe Duchenne Muscular Dystrophy Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2018-2023)
7.4 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size (2018-2033)
8.2 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Region (2018-2023)
8.4 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Duchenne Muscular Dystrophy Therapeutics Market Size (2018-2033)
9.2 Latin America Duchenne Muscular Dystrophy Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2018-2023)
9.4 Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size (2018-2033)
10.2 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2018-2023)
10.4 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Detail
11.1.2 Bristol-Myers Squibb Business Overview
11.1.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Introduction
11.1.4 Bristol-Myers Squibb Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2018-2023)
11.1.5 Bristol-Myers Squibb Recent Development
11.2 FibroGen (US)
11.2.1 FibroGen (US) Company Detail
11.2.2 FibroGen (US) Business Overview
11.2.3 FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Introduction
11.2.4 FibroGen (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2018-2023)
11.2.5 FibroGen (US) Recent Development
11.3 Italfarmaco (Italy)
11.3.1 Italfarmaco (Italy) Company Detail
11.3.2 Italfarmaco (Italy) Business Overview
11.3.3 Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Introduction
11.3.4 Italfarmaco (Italy) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2018-2023)
11.3.5 Italfarmaco (Italy) Recent Development
11.4 Marathon
11.4.1 Marathon Company Detail
11.4.2 Marathon Business Overview
11.4.3 Marathon Duchenne Muscular Dystrophy Therapeutics Introduction
11.4.4 Marathon Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2018-2023)
11.4.5 Marathon Recent Development
11.5 NS Pharma (US)
11.5.1 NS Pharma (US) Company Detail
11.5.2 NS Pharma (US) Business Overview
11.5.3 NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Introduction
11.5.4 NS Pharma (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2018-2023)
11.5.5 NS Pharma (US) Recent Development
11.6 PTC Therapeutics (US)
11.6.1 PTC Therapeutics (US) Company Detail
11.6.2 PTC Therapeutics (US) Business Overview
11.6.3 PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Introduction
11.6.4 PTC Therapeutics (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2018-2023)
11.6.5 PTC Therapeutics (US) Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Detail
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Duchenne Muscular Dystrophy Therapeutics Introduction
11.7.4 Pfizer Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2018-2023)
11.7.5 Pfizer Recent Development
11.8 ReveraGen BioPharma (US)
11.8.1 ReveraGen BioPharma (US) Company Detail
11.8.2 ReveraGen BioPharma (US) Business Overview
11.8.3 ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Introduction
11.8.4 ReveraGen BioPharma (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2018-2023)
11.8.5 ReveraGen BioPharma (US) Recent Development
11.9 Santhera Pharmaceuticals (Switzerland)
11.9.1 Santhera Pharmaceuticals (Switzerland) Company Detail
11.9.2 Santhera Pharmaceuticals (Switzerland) Business Overview
11.9.3 Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Introduction
11.9.4 Santhera Pharmaceuticals (Switzerland) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2018-2023)
11.9.5 Santhera Pharmaceuticals (Switzerland) Recent Development
11.10 Sarepta Therapeutics (US)
11.10.1 Sarepta Therapeutics (US) Company Detail
11.10.2 Sarepta Therapeutics (US) Business Overview
11.10.3 Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Introduction
11.10.4 Sarepta Therapeutics (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2018-2023)
11.10.5 Sarepta Therapeutics (US) Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Duchenne Muscular Dystrophy Therapeutics Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of Pain Management Drugs
Table 3. Key Players of Corticosteroids
Table 4. Key Players of Prednisolone
Table 5. Key Players of Prednisone
Table 6. Key Players of Deflazacort
Table 7. Global Duchenne Muscular Dystrophy Therapeutics Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 8. Global Duchenne Muscular Dystrophy Therapeutics Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 9. Global Duchenne Muscular Dystrophy Therapeutics Market Size by Region (2018-2023) & (US$ Million)
Table 10. Global Duchenne Muscular Dystrophy Therapeutics Market Share by Region (2018-2023)
Table 11. Global Duchenne Muscular Dystrophy Therapeutics Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 12. Global Duchenne Muscular Dystrophy Therapeutics Market Share by Region (2024-2033)
Table 13. Duchenne Muscular Dystrophy Therapeutics Market Trends
Table 14. Duchenne Muscular Dystrophy Therapeutics Market Drivers
Table 15. Duchenne Muscular Dystrophy Therapeutics Market Challenges
Table 16. Duchenne Muscular Dystrophy Therapeutics Market Restraints
Table 17. Global Duchenne Muscular Dystrophy Therapeutics Revenue by Players (2018-2023) & (US$ Million)
Table 18. Global Duchenne Muscular Dystrophy Therapeutics Market Share by Players (2018-2023)
Table 19. Global Top Duchenne Muscular Dystrophy Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy Therapeutics as of 2022)
Table 20. Ranking of Global Top Duchenne Muscular Dystrophy Therapeutics Companies by Revenue (US$ Million) in 2022
Table 21. Global 5 Largest Players Market Share by Duchenne Muscular Dystrophy Therapeutics Revenue (CR5 and HHI) & (2018-2023)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Duchenne Muscular Dystrophy Therapeutics Product Solution and Service
Table 24. Date of Enter into Duchenne Muscular Dystrophy Therapeutics Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2018-2023) & (US$ Million)
Table 27. Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Type (2018-2023)
Table 28. Global Duchenne Muscular Dystrophy Therapeutics Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 29. Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Type (2024-2033)
Table 30. Global Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2018-2023) & (US$ Million)
Table 31. Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Application (2018-2023)
Table 32. Global Duchenne Muscular Dystrophy Therapeutics Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 33. Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Application (2024-2033)
Table 34. North America Duchenne Muscular Dystrophy Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 35. North America Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 36. North America Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2024-2033) & (US$ Million)
Table 37. Europe Duchenne Muscular Dystrophy Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 38. Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 39. Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2024-2033) & (US$ Million)
Table 40. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 41. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Region (2018-2023) & (US$ Million)
Table 42. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Region (2024-2033) & (US$ Million)
Table 43. Latin America Duchenne Muscular Dystrophy Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 44. Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 45. Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2024-2033) & (US$ Million)
Table 46. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 47. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 48. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2024-2033) & (US$ Million)
Table 49. Bristol-Myers Squibb Company Detail
Table 50. Bristol-Myers Squibb Business Overview
Table 51. Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Product
Table 52. Bristol-Myers Squibb Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2018-2023) & (US$ Million)
Table 53. Bristol-Myers Squibb Recent Development
Table 54. FibroGen (US) Company Detail
Table 55. FibroGen (US) Business Overview
Table 56. FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Product
Table 57. FibroGen (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2018-2023) & (US$ Million)
Table 58. FibroGen (US) Recent Development
Table 59. Italfarmaco (Italy) Company Detail
Table 60. Italfarmaco (Italy) Business Overview
Table 61. Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Product
Table 62. Italfarmaco (Italy) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2018-2023) & (US$ Million)
Table 63. Italfarmaco (Italy) Recent Development
Table 64. Marathon Company Detail
Table 65. Marathon Business Overview
Table 66. Marathon Duchenne Muscular Dystrophy Therapeutics Product
Table 67. Marathon Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2018-2023) & (US$ Million)
Table 68. Marathon Recent Development
Table 69. NS Pharma (US) Company Detail
Table 70. NS Pharma (US) Business Overview
Table 71. NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Product
Table 72. NS Pharma (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2018-2023) & (US$ Million)
Table 73. NS Pharma (US) Recent Development
Table 74. PTC Therapeutics (US) Company Detail
Table 75. PTC Therapeutics (US) Business Overview
Table 76. PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product
Table 77. PTC Therapeutics (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2018-2023) & (US$ Million)
Table 78. PTC Therapeutics (US) Recent Development
Table 79. Pfizer Company Detail
Table 80. Pfizer Business Overview
Table 81. Pfizer Duchenne Muscular Dystrophy Therapeutics Product
Table 82. Pfizer Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2018-2023) & (US$ Million)
Table 83. Pfizer Recent Development
Table 84. ReveraGen BioPharma (US) Company Detail
Table 85. ReveraGen BioPharma (US) Business Overview
Table 86. ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Product
Table 87. ReveraGen BioPharma (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2018-2023) & (US$ Million)
Table 88. ReveraGen BioPharma (US) Recent Development
Table 89. Santhera Pharmaceuticals (Switzerland) Company Detail
Table 90. Santhera Pharmaceuticals (Switzerland) Business Overview
Table 91. Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Product
Table 92. Santhera Pharmaceuticals (Switzerland) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2018-2023) & (US$ Million)
Table 93. Santhera Pharmaceuticals (Switzerland) Recent Development
Table 94. Sarepta Therapeutics (US) Company Detail
Table 95. Sarepta Therapeutics (US) Business Overview
Table 96. Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product
Table 97. Sarepta Therapeutics (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2018-2023) & (US$ Million)
Table 98. Sarepta Therapeutics (US) Recent Development
Table 99. Research Programs/Design for This Report
Table 100. Key Data Information from Secondary Sources
Table 101. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Duchenne Muscular Dystrophy Therapeutics Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Duchenne Muscular Dystrophy Therapeutics Market Share by Type: 2022 VS 2033
Figure 3. Pain Management Drugs Features
Figure 4. Corticosteroids Features
Figure 5. Prednisolone Features
Figure 6. Prednisone Features
Figure 7. Deflazacort Features
Figure 8. Global Duchenne Muscular Dystrophy Therapeutics Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 9. Global Duchenne Muscular Dystrophy Therapeutics Market Share by Application: 2022 VS 2033
Figure 10. Hospitals Case Studies
Figure 11. Clinics Case Studies
Figure 12. Home Care Case Studies
Figure 13. Duchenne Muscular Dystrophy Therapeutics Report Years Considered
Figure 14. Global Duchenne Muscular Dystrophy Therapeutics Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 15. Global Duchenne Muscular Dystrophy Therapeutics Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 16. Global Duchenne Muscular Dystrophy Therapeutics Market Share by Region: 2022 VS 2033
Figure 17. Global Duchenne Muscular Dystrophy Therapeutics Market Share by Players in 2022
Figure 18. Global Top Duchenne Muscular Dystrophy Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy Therapeutics as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by Duchenne Muscular Dystrophy Therapeutics Revenue in 2022
Figure 20. North America Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 21. North America Duchenne Muscular Dystrophy Therapeutics Market Share by Country (2018-2033)
Figure 22. United States Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 23. Canada Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. Europe Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. Europe Duchenne Muscular Dystrophy Therapeutics Market Share by Country (2018-2033)
Figure 26. Germany Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. France Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. U.K. Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Italy Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Russia Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. Nordic Countries Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Share by Region (2018-2033)
Figure 34. China Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. Japan Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. South Korea Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. Southeast Asia Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. India Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 39. Australia Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 40. Latin America Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 41. Latin America Duchenne Muscular Dystrophy Therapeutics Market Share by Country (2018-2033)
Figure 42. Mexico Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. Brazil Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Share by Country (2018-2033)
Figure 46. Turkey Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 47. Saudi Arabia Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 48. Bristol-Myers Squibb Revenue Growth Rate in Duchenne Muscular Dystrophy Therapeutics Business (2018-2023)
Figure 49. FibroGen (US) Revenue Growth Rate in Duchenne Muscular Dystrophy Therapeutics Business (2018-2023)
Figure 50. Italfarmaco (Italy) Revenue Growth Rate in Duchenne Muscular Dystrophy Therapeutics Business (2018-2023)
Figure 51. Marathon Revenue Growth Rate in Duchenne Muscular Dystrophy Therapeutics Business (2018-2023)
Figure 52. NS Pharma (US) Revenue Growth Rate in Duchenne Muscular Dystrophy Therapeutics Business (2018-2023)
Figure 53. PTC Therapeutics (US) Revenue Growth Rate in Duchenne Muscular Dystrophy Therapeutics Business (2018-2023)
Figure 54. Pfizer Revenue Growth Rate in Duchenne Muscular Dystrophy Therapeutics Business (2018-2023)
Figure 55. ReveraGen BioPharma (US) Revenue Growth Rate in Duchenne Muscular Dystrophy Therapeutics Business (2018-2023)
Figure 56. Santhera Pharmaceuticals (Switzerland) Revenue Growth Rate in Duchenne Muscular Dystrophy Therapeutics Business (2018-2023)
Figure 57. Sarepta Therapeutics (US) Revenue Growth Rate in Duchenne Muscular Dystrophy Therapeutics Business (2018-2023)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed